Cancer Treatment as Individual as Your Fingerprint

Cancer Treatment as Individual as Your Fingerprint

The future of cancer care is here—where treatment is personalized, not standardized.

First Ascent Biomedical delivers a breakthrough in oncology: rapid, personalized treatment insights for any cancer category in just 10 days.

The future of cancer care is here—where treatment is personalized, not standardized.

First Ascent Biomedical delivers a breakthrough in oncology: rapid, personalized treatment insights for any cancer category in an average of 10 days.

First Ascent Biomedical - For Patients

For Patients and Caregivers

We work with your care team to test and validate treatment options using your own tumor cells—often delivering new hope in approximately 10 days or less.

First Ascent Biomedical - For Physicians

For Physicians

Our platform delivers patient-specific data to support precision care. Physicians gain new clarity based on what most impacts the patient’s cancer when standard protocols fall short.

First Ascent Biomedical - For Industry

For Biopharma

Our platform offers pharmaceutical companies an entirely new lens for drug development, target identification, and biomarker discovery.

First Ascent Biomedical - For Patients

For Patients and Caregivers

If you’ve heard “there’s nothing more we can do,” we may be able to help. We work with your care team to test and validate treatment options using your own tumor cells—often delivering new hope in less than 10 days.

First Ascent Biomedical - For Physicians

For Physicians

Our platform delivers tailored treatment recommendations backed by real-world tumor response data. Physicians gain new clarity based on what most impacts the patient’s cancer when standard protocols fall short.

First Ascent Biomedical - For Industry

For Biopharma

Our platform provides pharmaceutical companies with a new perspective for drug development, target identification, and biomarker discovery.

About First Ascent Biomedical

Our proprietary live-cell approach is the first and only platform capable of testing up to 150+ FDA-approved therapies and combinations in parallel on both liquid and solid cancers—delivering precise, patient-specific evidence on how an individual’s cancer responds in approximately 10 days or less.

“I kicked cancer’s butt!”

Meet Logan, 8 years old

First Ascent Biomedical - For Patients

For Patients & Caregivers

If you’ve heard “there’s nothing more we can do,” we may be able to help. We work with your care team to test and validate treatment options using your own tumor cells—often delivering new hope in <2 weeks.

First Ascent Biomedical - For Physicians

For Physicians

Validated and published studies with leading cancer centers, oncologists can take advantage of first-in-kind treatment planning technology with average 10-day turnaround.

First Ascent Biomedical - For Industry

For Industry

Demonstrated with leading industry partners, our drug sensitivity testing and causal ML platform can accelerate the drug development pipeline for all types of cancer.

The xDrive Platform

Ex Vivo Drug Response Identification & Validation Engine
Two powerful applications. One transformative platform.
At the core of our approach is xDRIVE—a first-in-kind oncology decision support system that combines:

  • Functional Drug Validation – Assessing live cancer cell response to drugs outside the body.
  • Genomic Sequencing – Identifying molecular markers through DNA and RNA sequencing.
  • AI Cancer Weakness Mapping – Pinpointing likely effective treatments based on unique solid and liquid cancer characteristics.

For Patients and Oncologists: xDrive provides patient-specific evidence of how a tumor/cancer responds to drugs in approximately 10 days or less, for faster, more effective care.

For Pharma and Biotech: DxPP delivers critical insights, shortening early-stage drug development timelines and reducing investment.

Real-World Impact

83%

Up to 83% of patients respond better over doctors’ choice or standard of care

8.5x

longer progression-free survival

10 day average

personalized insights delivered to the care team in an average of 10 days

Validated by scientific publications and strengthened through collaborations with top-tier cancer treatment centers and academic medical institutions nationwide, these results demonstrate the promise of our approach in treating the most challenging cancers.

Publication and Pharma Partners

The Latest First Ascent Biomedical News